Sichuan Mingbo Kanglin Medical Technology Co., Ltd. – Trademark Portfolio

Entity Type: 99

Sichuan Mingbo Kanglin Medical Technology Co., Ltd. holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 25 (Clothing) — 2 filings in this category. Currently, 1 trademark is registered and 1 is pending. Notable registered marks include MALLYTEEDS. The owner is based in Chengdu,Sichuan.

Xingsheng West Rd,Jinniu High-tech Park

No. 05B, 16th Floor, Bldg 3, No. 2

Chengdu,Sichuan 610000 , CN

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Sichuan Mingbo Kanglin Medical Technology Co., Ltd.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

25
Clothing (2 filings)

Clothing, footwear, headgear

Frequently Asked Questions

How many trademarks does Sichuan Mingbo Kanglin Medical Technology Co., Ltd. have?

Sichuan Mingbo Kanglin Medical Technology Co., Ltd. has 2 U.S. trademarks filed with the USPTO. Of these, 1 registered, 1 pending.

What trademark classes does Sichuan Mingbo Kanglin Medical Technology Co., Ltd. file in?

Sichuan Mingbo Kanglin Medical Technology Co., Ltd. files trademarks across 1 Nice Classification class. The most active classes are Class 25 (Clothing). Class 25 covers clothing, footwear, headgear.

What are Sichuan Mingbo Kanglin Medical Technology Co., Ltd.'s most well-known trademarks?

Sichuan Mingbo Kanglin Medical Technology Co., Ltd.'s registered trademark portfolio includes well-known marks such as MALLYTEEDS. These are among 1 currently registered trademark in the portfolio.

What is Sichuan Mingbo Kanglin Medical Technology Co., Ltd.'s trademark registration success rate?

Sichuan Mingbo Kanglin Medical Technology Co., Ltd. has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 1 application is pending review.